Aeglea Bio Therapeutics Inc

Change company Symbol lookup

Select an option...

AGLE Aeglea Bio Therapeutics Inc

ACNT Ascent Industries Co

FATH Fathom Digital Manufacturing Corp

PAYX Paychex Inc

WAVD Wavedancer Inc

RNXT RenovoRx Inc

GBNY Generations Bancorp NY Inc

POL Polished.Com Inc

MDGS Medigus Ltd

GTH Genetron Holdings Ltd

Go

Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will...(PR Newswire)

Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced it will effect a...(PR Newswire)

Scott Burrows, former Arcutis Biotherapeutics CFO, assumes role as Chief Financial Officer Heidy Abreu King-Jones, former Provention Bio CLO & Corporate Secretary, assumes role as Chief Legal Officer & Corporate Secretary (PR Newswire)

Acquisition of Spyre's assets and concurrent oversubscribed $210.0 million private investment positions the company to advance a potentially best-in-class inflammatory bowel disease (IBD) portfolio, including a4b7 and TL1A programs (PR Newswire)

Global rights to pegzilarginase in development for Arginase 1 Deficiency sold to Immedica Pharma for $15 million upfront cash proceeds and up to $100 million of contingent milestone payments Marketing Authorisation Application for pegzilarginase is...(PR Newswire)

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (MarketWatch)